See more : Vox Valor Capital Limited (VOX.L) Income Statement Analysis – Financial Results
Complete financial analysis of Haemonetics Corporation (HAE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Haemonetics Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Hawk Systems, Inc. (HWSY) Income Statement Analysis – Financial Results
- Bit Brother Limited (BETS) Income Statement Analysis – Financial Results
- Communications Systems, Inc. (JCS) Income Statement Analysis – Financial Results
- Melco Holdings Inc. (6676.T) Income Statement Analysis – Financial Results
- Lida Resources Inc. (LIDA.CN) Income Statement Analysis – Financial Results
Haemonetics Corporation (HAE)
About Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.31B | 1.17B | 993.20M | 870.46M | 988.48M | 967.58M | 903.92M | 886.12M | 909.68M | 910.37M | 938.51M | 891.99M | 727.84M | 676.69M | 645.43M | 597.88M | 516.44M | 449.61M | 419.73M | 383.60M | 364.23M | 336.96M | 319.97M | 293.86M | 277.92M | 282.10M | 285.80M | 309.80M | 278.20M | 262.40M | 248.40M | 216.30M | 176.40M | 157.30M |
| Cost of Revenue | 617.51M | 553.56M | 487.69M | 472.63M | 503.97M | 550.04M | 492.02M | 507.62M | 503.80M | 475.96M | 470.14M | 463.86M | 358.60M | 321.49M | 307.95M | 289.71M | 258.72M | 222.31M | 199.20M | 185.72M | 192.11M | 182.26M | 165.14M | 126.95M | 121.70M | 124.00M | 127.10M | 137.80M | 110.50M | 103.90M | 94.20M | 88.80M | 78.50M | 0.00 |
| Gross Profit | 691.55M | 615.10M | 505.50M | 397.84M | 484.51M | 417.54M | 411.91M | 378.49M | 405.87M | 434.42M | 468.37M | 428.13M | 369.24M | 355.21M | 337.48M | 308.17M | 257.73M | 227.30M | 220.54M | 197.88M | 172.12M | 154.70M | 154.83M | 166.91M | 156.22M | 158.10M | 158.70M | 172.00M | 167.70M | 158.50M | 154.20M | 127.50M | 97.90M | 157.30M |
| Gross Profit Ratio | 52.83% | 52.63% | 50.90% | 45.70% | 49.02% | 43.15% | 45.57% | 42.71% | 44.62% | 47.72% | 49.91% | 48.00% | 50.73% | 52.49% | 52.29% | 51.54% | 49.90% | 50.56% | 52.54% | 51.58% | 47.26% | 45.91% | 48.39% | 56.80% | 56.21% | 56.04% | 55.53% | 55.52% | 60.28% | 60.40% | 62.08% | 58.95% | 55.50% | 100.00% |
| Research & Development | 54.44M | 50.13M | 46.80M | 32.86M | 30.88M | 35.71M | 39.23M | 37.56M | 45.57M | 54.19M | 54.20M | 48.64M | 36.80M | 32.66M | 26.38M | 23.86M | 24.32M | 23.88M | 26.52M | 19.99M | 17.79M | 19.51M | 19.51M | 19.04M | 14.93M | 15.10M | 17.90M | 19.00M | 18.50M | 16.70M | 15.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 424.68M | 369.48M | 335.16M | 271.49M | 295.38M | 293.78M | 313.42M | 299.23M | 320.07M | 335.19M | 363.24M | 314.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.10M | 7.20M | 4.40M | 2.70M | 4.30M | 4.50M | 3.10M | 2.50M | 3.90M | 4.50M | 3.60M | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 431.78M | 376.68M | 339.56M | 274.19M | 299.68M | 298.28M | 316.52M | 301.73M | 323.97M | 339.69M | 366.84M | 318.81M | 245.26M | 213.90M | 214.48M | 198.74M | 163.12M | 137.07M | 121.35M | 118.04M | 108.45M | 97.71M | 88.87M | 86.73M | 82.76M | 86.70M | 86.90M | 92.30M | 81.80M | 75.70M | 75.90M | 77.20M | 61.00M | 0.00 |
| Other Expenses | 40.45M | 32.26M | 47.41M | 32.83M | 50.60M | 0.00 | 0.00 | -8.10M | 87.67M | 5.44M | 1.71M | -6.54M | 0.00 | -1.89M | 13.34M | 0.00 | 0.00 | -5.48M | -26.35M | -100.00K | 0.00 | 0.00 | 0.00 | 4.61M | 24.91M | 24.60M | 22.90M | 12.30M | 13.10M | 13.70M | 10.70M | 8.50M | 7.00M | 0.00 |
| Operating Expenses | 526.67M | 459.06M | 433.78M | 339.88M | 330.56M | 333.99M | 355.75M | 339.28M | 369.54M | 393.88M | 421.04M | 367.45M | 282.06M | 244.66M | 240.86M | 222.60M | 187.44M | 155.48M | 121.52M | 137.93M | 126.24M | 117.22M | 108.39M | 110.39M | 122.59M | 126.40M | 127.70M | 123.60M | 113.40M | 106.10M | 102.40M | 85.70M | 68.00M | 0.00 |
| Cost & Expenses | 1.14B | 459.06M | 921.47M | 812.50M | 834.53M | 884.03M | 847.77M | 846.90M | 873.34M | 869.83M | 891.18M | 831.31M | 640.67M | 566.15M | 548.81M | 512.31M | 446.15M | 377.79M | 320.72M | 323.66M | 318.35M | 299.48M | 273.52M | 237.34M | 244.29M | 250.40M | 254.80M | 261.40M | 223.90M | 210.00M | 196.60M | 174.50M | 146.50M | 0.00 |
| Interest Income | 0.00 | 13.00M | 5.80M | 9.40M | 13.50M | 9.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 384.00K | 399.00K | 1.97M | 0.00 | 7.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.02M | 14.63M | 17.12M | 16.83M | 16.20M | 9.91M | 4.53M | 8.10M | 9.47M | 9.38M | 10.93M | 6.54M | 0.00 | 6.00K | 742.00K | 64.00K | 0.00 | 97.00K | 0.00 | 0.00 | 0.00 | 0.00 | 13.58M | 59.39M | 13.10M | 0.00 | 74.90M | 0.00 | 0.00 | 0.00 | 0.00 | 1.60M | 1.60M | 0.00 |
| Depreciation & Amortization | 97.22M | 93.31M | 97.75M | 84.29M | 110.29M | 109.42M | 89.25M | 89.73M | 89.91M | 86.05M | 81.74M | 65.48M | 49.97M | 48.15M | 43.24M | 36.46M | 31.20M | 27.50M | 25.15M | 27.58M | 30.15M | 28.43M | 25.62M | 24.50M | 24.91M | 24.60M | 22.90M | 12.30M | 13.10M | 13.70M | 10.70M | 8.50M | 7.00M | 0.00 |
| EBITDA | 265.58M | 249.34M | 178.50M | 142.25M | 264.24M | 192.96M | 153.03M | 70.35M | 45.97M | 125.72M | 127.04M | 124.58M | 139.46M | 158.23M | 125.25M | 121.53M | 101.48M | 101.10M | 124.17M | 87.52M | 77.44M | 65.91M | 72.06M | 81.02M | 73.13M | 51.20M | 53.90M | 72.00M | 67.40M | 66.10M | 62.50M | 50.30M | 36.90M | 157.30M |
| EBITDA Ratio | 20.29% | 21.34% | 17.06% | 16.34% | 26.73% | 19.94% | 16.09% | 14.55% | 13.89% | 4.45% | 5.04% | 6.80% | 11.66% | 23.51% | 15.03% | 20.74% | 19.27% | 22.23% | 22.63% | 22.78% | 20.60% | 18.85% | 25.00% | 34.44% | 23.56% | 18.15% | 26.91% | 18.30% | 23.08% | 24.43% | 24.07% | 23.16% | 20.58% | 100.00% |
| Operating Income | 164.88M | 156.03M | 80.75M | 57.96M | 153.95M | 83.55M | 56.16M | -19.38M | -43.98M | 40.54M | 47.33M | 56.44M | 88.76M | 110.55M | 83.28M | 85.57M | 70.29M | 62.75M | 99.02M | 59.94M | 45.88M | 37.48M | 36.45M | 13.42M | 33.63M | 31.70M | 31.00M | 48.40M | 54.30M | 52.40M | 51.80M | 41.80M | 29.90M | 157.30M |
| Operating Income Ratio | 12.60% | 13.35% | 8.13% | 6.66% | 15.57% | 8.63% | 6.21% | -2.19% | -4.84% | 4.45% | 5.04% | 6.33% | 12.19% | 16.34% | 12.90% | 14.31% | 13.61% | 13.96% | 23.59% | 15.63% | 12.60% | 11.12% | 11.39% | 4.57% | 12.10% | 11.24% | 10.85% | 15.62% | 19.52% | 19.97% | 20.85% | 19.33% | 16.95% | 100.00% |
| Total Other Income/Expenses | -13.02M | -14.63M | -17.12M | 14.95M | -16.20M | -9.91M | 3.48M | -8.10M | -97.14M | -9.38M | -10.93M | -6.54M | 740.00K | -467.00K | -2.01M | -565.00K | 7.02M | 9.59M | 7.86M | -102.00K | -65.00K | 1.13M | 2.06M | 3.91M | 3.25M | 969.00K | -26.50M | 2.30M | 900.00K | 100.00K | -1.00M | -1.80M | -2.20M | -157.30M |
| Income Before Tax | 151.87M | 141.40M | 63.63M | 72.91M | 87.15M | 73.63M | 59.63M | -27.48M | -53.46M | 31.17M | 36.40M | 49.90M | 89.50M | 110.08M | 81.27M | 85.00M | 77.30M | 72.34M | 106.88M | 59.84M | 45.81M | 38.61M | 38.51M | 17.33M | 27.33M | 32.60M | 4.50M | 50.70M | 55.20M | 52.50M | 50.80M | 40.00M | 27.70M | 0.00 |
| Income Before Tax Ratio | 11.60% | 12.10% | 6.41% | 8.38% | 8.82% | 7.61% | 6.60% | -3.10% | -5.88% | 3.42% | 3.88% | 5.59% | 12.30% | 16.27% | 12.59% | 14.22% | 14.97% | 16.09% | 25.46% | 15.60% | 12.58% | 11.46% | 12.03% | 5.90% | 9.83% | 11.56% | 1.57% | 16.37% | 19.84% | 20.01% | 20.45% | 18.49% | 15.70% | 0.00% |
| Income Tax Expense | 34.31M | 26.00M | 20.25M | -6.56M | 10.63M | 18.61M | 14.06M | -1.21M | 2.16M | 14.27M | 1.25M | 11.10M | 22.61M | 30.10M | 22.90M | 25.70M | 25.32M | 23.23M | 37.81M | 20.20M | 16.49M | 10.23M | 10.78M | 10.09M | 8.47M | 11.40M | 3.90M | 17.70M | 19.30M | 18.90M | 19.30M | 15.20M | 9.70M | 0.00 |
| Net Income | 117.56M | 115.40M | 43.38M | 79.47M | 76.53M | 55.02M | 45.57M | -26.27M | -55.62M | 16.90M | 35.15M | 38.80M | 66.89M | 79.98M | 58.38M | 59.30M | 51.98M | 49.11M | 69.08M | 39.64M | 29.32M | 28.38M | 30.03M | 7.24M | 19.00M | 21.10M | -24.80M | 33.00M | 35.90M | 33.60M | 31.50M | 24.80M | 18.00M | 0.00 |
| Net Income Ratio | 8.98% | 9.87% | 4.37% | 9.13% | 7.74% | 5.69% | 5.04% | -2.96% | -6.11% | 1.86% | 3.75% | 4.35% | 9.19% | 11.82% | 9.04% | 9.92% | 10.07% | 10.92% | 16.46% | 10.33% | 8.05% | 8.42% | 9.38% | 2.46% | 6.84% | 7.48% | -8.68% | 10.65% | 12.90% | 12.80% | 12.68% | 11.47% | 10.20% | 0.00% |
| EPS | 2.32 | 2.27 | 0.85 | 1.57 | 1.51 | 1.07 | 0.86 | -0.51 | -1.09 | 0.33 | 0.68 | 0.76 | 1.30 | 1.59 | 1.15 | 1.17 | 1.00 | 0.92 | 1.29 | 0.77 | 0.60 | 0.57 | 0.57 | 0.14 | 0.30 | 0.39 | -0.47 | 0.61 | 0.66 | 0.61 | 0.56 | 0.45 | 0.33 | 0.26 |
| EPS Diluted | 2.29 | 2.24 | 0.84 | 1.55 | 1.48 | 1.04 | 0.85 | -0.51 | -1.09 | 0.32 | 0.67 | 0.74 | 1.30 | 1.56 | 1.12 | 1.14 | 0.97 | 0.89 | 1.25 | 0.75 | 0.60 | 0.56 | 0.56 | 0.14 | 0.29 | 0.39 | -0.47 | 0.60 | 0.65 | 0.59 | 0.55 | 0.44 | 0.32 | 0.25 |
| Weighted Avg Shares Out | 50.71M | 50.78M | 51.05M | 50.69M | 50.69M | 51.53M | 52.76M | 51.51M | 50.91M | 51.53M | 51.61M | 51.35M | 50.73M | 50.15M | 50.90M | 50.78M | 51.65M | 53.49M | 52.96M | 51.05M | 48.87M | 49.18M | 52.43M | 50.60M | 52.17M | 53.49M | 52.77M | 54.38M | 54.39M | 55.54M | 55.75M | 55.73M | 55.38M | 55.60M |
| Weighted Avg Shares Out (Dil) | 51.40M | 51.42M | 51.35M | 51.29M | 51.82M | 52.94M | 53.50M | 51.52M | 50.91M | 52.09M | 52.38M | 52.26M | 51.59M | 51.19M | 52.13M | 52.35M | 53.49M | 55.30M | 54.95M | 52.85M | 49.28M | 50.10M | 54.31M | 52.01M | 53.00M | 53.77M | 53.33M | 54.83M | 55.23M | 56.95M | 57.80M | 57.01M | 57.14M | 55.60M |
After Plunging -15.88% in 4 Weeks, Here's Why the Trend Might Reverse for Haemonetics (HAE)
Haemonetics (HAE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
HAE vs. BSX: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.
Top 3 Health Care Stocks That Are Set To Fly This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System
BOSTON , Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure...
Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises
Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.
Is Haemonetics (HAE) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Down -14.6% in 4 Weeks, Here's Why Haemonetics (HAE) Looks Ripe for a Turnaround
Haemonetics (HAE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the...
Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Olga Guyette – Vice President, Investor Relations and Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call...
HAE or BSX: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Source: https://incomestatements.info
Category: Stock Reports